Esprit news from FierceBiotech
News
Allergan injects $370M into Esprit buyout
Allergan is taking some of the money it makes from Botox to buy Esprit Pharma for $370 million in cash. New Jersey-based Esprit makes Sanctura for overactive bladder and is launching Sanctura XR.... Read more...
Press Release: Depomed Reaquires Rights to ProQuin XR
Press Release: Depomed Reaquires Rights to ProQuin XR
... Read more...ALSO NOTED: Esprit hands over drug; Diatos gins $12.8M; Swans dead of avian flu; and much more...
> Esprit Pharma has agreed to pay $15 million and return ownership of a urinary tract infection drug to Depomed. Report
> France's Diatos has raised $12.8 million in its fourth round of venture capital. Report
> There's new evidence to …
... Read more...Press Release: Kiadis Pharma Raises Euro 15 Million to Advance Oncology Pipeline
Press Release: Kiadis Pharma Raises Euro 15 Million to Advance Oncology Pipeline
... Read more...Depomed demands $105M from Esprit Pharma
Depomed is demanding more than $105 million from Esprit Pharma to satisfy claims that Esprit violated their licensing deal on ProQuin XR for urinary tract infections. Depomed says Esprit failed to make a $10 million milestone payment due December 15, among other things. Depomed of Menlo Park, CA is also demanding binding arbitration to settle its claims.
- see the release on the damages claim
Related Article:
Esprit adds $91M in VC. Report
Press Release: Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
Press Release: Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
... Read more...ALSO NOTED: Ariad selling shares; Indevus gains milestone; Barr closing on Pliva; and much more...
> Ariad Pharmaceuticals is selling 3.1 million shares in a public offering. Report
> Indevus Pharmaceuticals has received a $10 million milestone payment from Esprit Pharma, the company's partner in the U.S. for Sanctura and and Sanctura XR. …
... Read more...VC: Espirit Pharma lands $91M in VC
Espirit Pharma lands $91M in VC
VC: Esprit adds $91M, ESBATech gains $41M
Esprit Pharma has rounded up almost $91 million in its second round of venture capital. Firms participating in the Series B round included existing investors New Enterprise Associates, Apax Partners, Domain Associates and Montagu Newhall Global Partners plus new investors Oak Investment Partners and clients advised by Performance Equity Management. "While it's been just over a year since we began operations, Esprit has experienced strong growth," said John T. Spitznagel, Esprit's chairman …
... Read more...DEALS: AstraZeneca buys CAT for $1.3B
AstraZeneca buys CAT for $1.3B
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
